Please login to the form below

Not currently logged in
Email:
Password:

Pfizer's Robert Clark to move to Novo Nordisk

Will join firm’s US operations as vice president of regulatory affairs

Novo Nordisk has appointed Robert Clark as vice president of regulatory affairs in a role that will see him lead the Danish pharma company's US regulatory team.

He will also be tasked with maintaining “relationships with key individuals and agencies outside of Novo Nordisk that play a specific role in the US Food and Drug Administration's (FDA) review and approval process”, Novo said.

Clark will join the company on May 14 from Pfizer, where he was US regulatory strategy head, leading or supporting approvals of new cardiovascular, endocrine, women's health and anti-infective medicines.

"Bob is bringing 27 years of experience and knowledge of the global and US regulatory environment, and it's that know-how we require for an increasingly complex pharmaceutical marketplace," said Anne Philips, corporate vice president of clinical development, medical and regulatory affairs at Novo Nordisk.

"Novo Nordisk has one of the most promising diabetes pipelines in the industry, and having a respected leader known to regulatory authorities will help us achieve our ongoing mission to bring new therapies to patients."

9th May 2012

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics